Evidence map›Paper›PMID 34379796›Full record

ArticlePhotochemistry and photobiology2022

Dual Function Antibody Conjugates for Multimodal Imaging and Photoimmunotherapy of Cancer Cells.

Mohammad A Saad, Marvin Xavierselvan, Hamza A Sharif, Scott Selfridge, Robert Pawle, Mark Varvares, Srivalleesha Mallidi, Tayyaba Hasan

Abstract read
In one paragraph

Article in Photochemistry and photobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohammad A SaadWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3337-2076
Marvin XavierselvanDepartment of Biomedical Engineering, Science and Technology Center, Tufts University, Medford, MA, USA.
Hamza A SharifAlbany Medical College, Albany, NY, USA.
Scott SelfridgeAkita Innovations, North Billerica, MA, USA.
Robert PawleAkita Innovations, North Billerica, MA, USA.
Mark VarvaresDepartment of Otolaryngology Head and Neck Surgery, Harvard Medical School, The Massachusetts Eye and Ear, Boston, MA, USA.
Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1547-1764
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Brian William Pogue · 2001 to 2026
$27.9M
Dual function theranostic constructs for photoacoustic guided surgery and photodynamic therapyR01CA231606 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2019 to 2025
$3.1M
VisualSonics Photoacoustic and Ultrasound Imaging SystemS10OD012326 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2012 to 2012
$912k
Optical imaging guided resection and photodynamic therapy of glioma with targeted photoactivable agentsR21CA220143 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2017 to 2019
$390k
NCI NIH HHS P01 CA084203NCI NIH HHS R01 CA231606NCI NIH HHS R21 CA220143NIH HHS S10 OD012326
6 · The paper itself

Abstract

Precision imaging, utilizing molecular targeted agents, is an important tool in cancer diagnostics and guiding therapies. While there are limitations associated with single mode imaging probes, multimodal molecular imaging probes enabling target visualization through complementary imaging technologies provides an attractive alternative. However, there are several challenges associated with designing molecular probes carrying contrast agents for complementary multimodal imaging. Here, we propose a dual function antibody conjugate (DFAC) comprising an FDA approved photosensitizer Benzoporphyrin derivative (BPD) and a naphthalocyanine-based photoacoustic dye (SiNc(OH)) for multimodal infrared (IR) imaging. While fluorescence imaging, through BPD, provides sensitivity, complementing it with photoacoustic imaging, through SiNc(OH), provides a depth-resolved spatial resolution much beyond the optical diffusion limits of fluorescence measurements. Through a series of in vitro experiments, we demonstrate the development and utilization of DFACs for multimodal imaging and photodynamic treatment of squamous cell carcinoma (A431) cell line. The proposed DFACs have potential use in precision imaging applications such as guiding tumor resection surgeries and photodynamic treatment of residual microscopic disease thereby minimizing local recurrence. The data demonstrated in this study merits further investigation for its preclinical and clinical translation.

Indexed as

NeoplasmsPhototherapyCell Line, TumorImmunotherapyMultimodal ImagingOptical ImagingPhotosensitizing AgentsPhotosensitizing Agents

Identifiers

PMID34379796
PMCPMC10038131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.